Nivolumab Plus Cabozantinib vs Sunitinib for First-Line Treatment of Advanced Renal Cell Carcinoma (aRCC): 3-Year Follow-Up From the Phase 3 CheckMate 9 ER Trial (vol 41, pg 603, 2023)

被引：1
作者：
Motzer, Robert J.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 21期
关键词：
D O I：
10.1200/JCO.23.00901
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3767 / 3767
页数：1
相关论文
共 50 条
[21]   Nivolumab plus cabozantinib (NIVO plus CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER. [J].
Motzer, Robert J. ;
Choueiri, Toni K. ;
Powles, Thomas ;
Burotto, Mauricio ;
Bourlon, Maria Teresa ;
Hsieh, James J. ;
Maruzzo, Marco ;
Shah, Amishi Yogesh ;
Suarez, Cristina ;
Barrios, Carlos H. ;
Richardet, Martin Eduardo ;
Porta, Camillo ;
Goh, Jeffrey C. ;
Tomita, Yoshihiko ;
Bedke, Jens ;
Zhang, Joshua ;
Simsek, Burcin ;
Scheffold, Christian ;
Gupta, Saurabh ;
Apolo, Andrea B. .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[22]   Nivolumab plus cabozantinib (N plus C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial. [J].
Apolo, Andrea B. ;
Powles, Thomas ;
Burotto, Mauricio ;
Bourlon, Maria Teresa ;
Hsieh, James J. ;
Basso, Umberto ;
Shah, Amishi Yogesh ;
Suarez, Cristina ;
Porta, Camillo ;
Barrios, Carlos H. ;
Gurney, Howard ;
Kessler, Elizabeth R. ;
Retz, Margitta ;
George, Saby ;
Escudier, Bernard ;
Zhang, Joshua ;
Simsek, Burcin ;
Scheffold, Christian ;
Motzer, Robert J. ;
Choueiri, Toni K. .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[23]   Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab plus ipilimumab (N plus I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC) [J].
Motzer, R. J. ;
Tannir, N. M. ;
McDermott, D. F. ;
Burotto, M. ;
Choueiri, T. K. ;
Hammers, H. J. ;
Plimack, E. R. ;
Porta, C. G. ;
George, S. ;
Powles, T. B. ;
Donskov, F. ;
Gurney, H. ;
Kollmannsberger, C. K. ;
Grimm, M-O. ;
Tomita, Y. ;
Rini, B. I. ;
McHenry, M. B. ;
Lee, C-W. ;
Escudier, B. .
ANNALS OF ONCOLOGY, 2021, 32 :S685-S687
[24]   Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab plus ipilimumab (N plus I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). [J].
Tannir, Nizar M. ;
Frontera, Osvaldo Aren ;
Hammers, Hans J. ;
Carducci, Michael Anthony ;
McDermott, David F. ;
Salman, Pamela ;
Escudier, Bernard ;
Beuselinck, Benoit ;
Amin, Asim ;
Porta, Camillo ;
George, Saby ;
Bracarda, Sergio ;
Tykodi, Scott S. ;
Powles, Thomas ;
Rini, Brian I. ;
Tomita, Yoshihiko ;
McHenry, M. Brent ;
Mekan, Sabeen Fatima ;
Motzer, Robert J. .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[25]   Long-term follow-up results of nivolumab plus cabozantinib versus sunitinib for advanced renal cell cancer: Checkmate 9ER trial [J].
Tarigopula, Vivek .
INDIAN JOURNAL OF UROLOGY, 2022, 38 (04) :317-318
[26]   Nivolumab plus ipilimumab (N plus I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy [J].
Albiges, L. ;
Tannir, N. ;
Burotto, M. ;
McDermott, D. F. ;
Plimack, E. R. ;
Barthelemy, P. ;
Porta, C. G. ;
Powles, T. B. ;
Donskov, F. ;
George, S. ;
Kollmannsberger, C. ;
Gurney, H. ;
Grimm, M-O. ;
Tomita, Y. ;
Castellano Gauna, D. ;
Rini, B. I. ;
Choueiri, T. K. ;
Saggi, S. S. ;
McHenry, M. B. ;
Motzer, R. J. .
ANNALS OF ONCOLOGY, 2020, 31 :S559-S560
[27]   First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial [J].
Janjigian, Yelena Y. ;
Ajani, Jaffer A. ;
Moehler, Markus ;
Shen, Lin ;
Garrido, Marcelo ;
Gallardo, Carlos ;
Wyrwicz, Lucjan ;
Yamaguchi, Kensei ;
Cleary, James M. ;
Elimova, Elena ;
Karamouzis, Michalis ;
Bruges, Ricardo ;
Skoczylas, Tomasz ;
Bragagnoli, Arinilda ;
Liu, Tianshi ;
Tehfe, Mustapha ;
Zander, Thomas ;
Kowalyszyn, Ruben ;
Pazo-Cid, Roberto ;
Schenker, Michael ;
Feeny, Kynan ;
Wang, Rui ;
Lei, Ming ;
Chen, Clara ;
Nathani, Raheel ;
Shitara, Kohei .
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17) :2012-2020
[28]   Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial [J].
Cella, David ;
Motzer, Robert J. ;
Suarez, Cristina ;
Blum, Steven, I ;
Ejzykowicz, Flavia ;
Hamilton, Melissa ;
Wallace, Joel F. ;
Simsek, Burcin ;
Zhang, Joshua ;
Ivanescu, Cristina ;
Apolo, Andrea B. ;
Choueiri, Toni K. .
LANCET ONCOLOGY, 2022, 23 (02) :292-303
[29]   Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial [J].
Motzer, Robert ;
Rini, Brian, I ;
McDermott, David F. ;
Frontera, Osvaldo Aren ;
Hammers, Hans J. ;
Carducci, Michael A. ;
Salman, Pamela ;
Escudier, Bernard ;
Beuselinck, Benoit ;
Amin, Asim ;
Porta, Camillo ;
George, Saby ;
Neiman, Victoria ;
Bracarda, Sergio ;
Tykodi, Scott S. ;
Barthelemy, Philippe ;
Leibowitz-Amit, Raya ;
Plimack, Elizabeth R. ;
Oosting, Sjoukje F. ;
Redman, Bruce ;
Melichar, Bohusiav ;
Powles, Thomas ;
Nathan, Paul ;
Oudard, Stephan ;
Pook, David ;
Choueiri, Toni K. ;
Donskov, Frede ;
Grimm, Marc-Oliver ;
Gurney, Howard ;
Heng, Daniel Y. C. ;
Kollmannsberger, Christian K. ;
Harrison, Michael R. ;
Tamita, Yoshihiko ;
Duran, Ignacio ;
Gruenwold, Viktor ;
McHenry, M. Brent ;
Mekan, Sabeen ;
Tannir, Nizar M. .
LANCET ONCOLOGY, 2019, 20 (10) :1370-1385
[30]   Long-Term Outcomes with First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up from CheckMate 012 [J].
Antonia, S. ;
Gettinger, S. ;
Borghaei, H. ;
Goldman, J. W. ;
Brahmer, J. ;
Ready, N. ;
Gerber, D. ;
Chow, L. ;
Juergens, R. ;
Laurie, S. ;
Shepherd, F. ;
Li, X. ;
Li, A. ;
Geese, W. ;
Hellmann, M. .
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) :S458-S458
12345